API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-the-us-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible-302210443.html
https://www.globenewswire.com/news-release/2024/07/02/2907367/0/en/Legend-Biotech-Announces-Positive-Overall-Survival-Results-of-Landmark-Phase-3-CARTITUDE-4-Trial-in-Multiple-Myeloma.html
https://www.globenewswire.com/news-release/2024/06/21/2902267/0/en/Starton-Therapeutics-Announces-100-Partial-Response-or-Better-in-Multiple-Myeloma-Patients-in-Interim-Top-line-Data-from-STAR-LLD-Phase-1b-Clinical-Trial.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-5-2024-58484.pdf
https://www.indianpharmapost.com/drug-approval/zydus-receives-final-approval-from-usfda-for-dexamethasone-tablets-15636
https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-new-drug-application-acceptance-by-singapore-health-sciences-authority-hsa-for-dextenza-for-treatment-of-ocular-inflammation-and-pain-following-ophthalmic-surgery-and-ocular-itching-associated-wi-302064649.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216283
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216282
https://www.fiercepharma.com/pharma/gsk-details-blenrep-combo-data-could-bring-multiple-myeloma-adc-back-life
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-says-blood-cancer-drug-meets-primary-goal-late-stage-trial-2023-11-27/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217695
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215768
https://www.asiaone.com/business/affamed-therapeutics-announces-completion-patient-enrollment-real-world-study-china
https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-completion-of-patient-enrollment-in-the-real-world-study-in-china-evaluating-the-safety-and-efficacy-of-dextenza-in-cataract-surgery-patients-301838072.html
https://www.prnewswire.com/news-releases/antengene-announces-xpovio-plus-bortezomib-and-dexamethasone-included-for-reimbursement-by-the-pbs-in-australia-for-the-treatment-of-relapsed-andor-refractory-multiple-myeloma-301839510.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217696
https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-approval-to-initiate-a-phase-3-registrational-clinical-trial-in-mainland-china-for-dextenza-for-the-treatment-of-ocular-inflammation-and-pain-following-ophthalmic-surgery-301797505.html
https://www.prnewswire.com/news-releases/karyopharm-and-menarini-group-receive-full-marketing-authorization-from-the-uk-medicines--healthcare-products-regulatory-agency-for-nexpovio-selinexor-in-combination-with-bortezomib-and-dexamethasone-for-the-treatment-of-adult-301751848.html
https://www.fiercepharma.com/pharma/novartis-isnt-done-shaking-things-sells-five-eyecare-drugs-harrow-130-million
https://www.prnewswire.com/news-releases/janssen-presents-efficacy-and-subgroup-analyses-from-maia-study-showing-long-term-results-of-darzalex-daratumumab-based-regimen-in-newly-diagnosed-transplant-ineligible-multiple-myeloma-301700443.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210470
https://www.clinicaltrialsarena.com/news/janssen-trial-multiple-myeloma/
https://endpts.com/those-big-billion-dollar-phiii-studies-martin-landray-says-they-can-be-done-for-a-tiny-fraction-of-the-cost/
https://www.pharmatimes.com/news/santen_launches_ducressa_for_post-cataract_surgery_1453357
https://news.cision.com/abbvie/r/nice-recommendation-expands-patient-eligibility-for-abbvie-s-ozurdex---dexamethasone-0-7mg-intravitr,c3613044
https://www.europeanpharmaceuticalreview.com/news/173574/trio-of-therapies-reduces-risk-of-death-in-patients-with-severe-covid-19/
https://www.pharmatimes.com/news/smc_approve_johnson_and_johnsons_systemic_light_chain_amyloidosis_therapy_1453205
http://www.pharmafile.com/news/721160/smc-accepts-first-licensed-treatment-newly-diagnosed-al-amyloidosis
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215604
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/latin-foods-market-issues-voluntary-nationwide-recall-artri-king-reforzado-con-ortiga-y-omega-3-due
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-15-2022-1655268880.pdf
https://www.clinicaltrialsarena.com/news/sanofi-multiple-myeloma-trial/
https://www.fiercepharma.com/pharma/seeking-shake-eye-inflammation-market-optifye-and-delsitech-partner-controlled-release-drops
https://padagis.com/padagis-annouces-the-fda-approval-and-launch-of-an-ab-rated-generic-version-of-tobradex-ophthalmic-suspension/
https://www.prnewswire.com/news-releases/antengene-announces-xpovio-approved-by-the-tga-in-australia-for-the-treatment-of-relapsed-andor-refractory-multiple-myeloma-and-triple-class-refractory-multiple-myeloma-301498919.html
https://www.fiercepharma.com/pharma/bristol-myers-squibbs-revlimid-finally-faces-competition-us-tevas-generic-launch
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212715
https://www.globenewswire.com/news-release/2022/02/07/2379644/0/en/Active-Biotech-announces-first-patient-dosed-in-the-combination-part-of-the-phase-Ib-IIa-study-of-tasquinimod-in-multiple-myeloma.html
https://www.prnewswire.com/news-releases/oncopeptides-phase-3-ocean-study-published-in-the-lancet-haematology-301460221.html
http://www.pharmafile.com/news/600992/nice-recommends-combination-treatment-patients-multiple-myeloma
https://www.fiercepharma.com/pharma/sanofi-johnson-johnson-collision-course-sarclisa-darzalex-4-drug-multiple-myeloma